VEGF165	0	7	B-Gene_or_gene_product
expressed	8	17	O
by	18	20	O
a	21	22	O
replication	23	34	O
-	34	35	O
deficient	35	44	O
recombinant	45	56	O
adenovirus	57	67	B-Organism
vector	68	74	O
induces	75	82	O
angiogenesis	83	95	O
in	96	98	O
vivo	99	103	O
.	103	104	O

To	106	108	O
evaluate	109	117	O
the	118	121	O
concept	122	129	O
that	130	134	O
localized	135	144	O
delivery	145	153	O
of	154	156	O
angiogenic	157	167	O
factors	168	175	O
via	176	179	O
virus	180	185	O
-	185	186	O
mediated	186	194	O
gene	195	199	O
transfer	200	208	O
may	209	212	O
be	213	215	O
useful	216	222	O
in	223	225	O
the	226	229	O
treatment	230	239	O
of	240	242	O
ischemic	243	251	O
disorders	252	261	O
,	261	262	O
the	263	266	O
replication	267	278	O
-	278	279	O
deficient	279	288	O
adenovirus	289	299	B-Organism
(	300	301	O
Ad	301	303	B-Organism
)	303	304	O
vector	305	311	O
AdCMV	312	317	O
.	317	318	O
VEGF165	318	325	B-Gene_or_gene_product
(	326	327	O
where	327	332	O
CMV	333	336	B-Organism
is	337	339	O
cytomegalovirus	340	355	B-Organism
and	356	359	O
VEGF	360	364	B-Gene_or_gene_product
is	365	367	O
vascular	368	376	B-Gene_or_gene_product
endothelial	377	388	I-Gene_or_gene_product
growth	389	395	I-Gene_or_gene_product
factor	396	402	I-Gene_or_gene_product
)	402	403	O
containing	404	414	O
the	415	418	O
cDNA	419	423	O
for	424	427	O
human	428	433	B-Organism
VEGF165	434	441	B-Gene_or_gene_product
,	441	442	O
a	443	444	O
secreted	445	453	O
endothelial	454	465	B-Cell
cell	466	470	I-Cell
-	470	471	O
specific	471	479	O
angiogenic	480	490	O
growth	491	497	O
factor	498	504	O
,	504	505	O
was	506	509	O
constructed	510	521	O
.	521	522	O

Human	523	528	B-Cell
umbilical	529	538	I-Cell
vein	539	543	I-Cell
endothelial	544	555	I-Cell
cells	556	561	I-Cell
(	562	563	O
HUVECs	563	569	B-Cell
)	569	570	O
and	571	574	O
rat	575	578	B-Cell
aorta	579	584	I-Cell
smooth	585	591	I-Cell
muscle	592	598	I-Cell
cells	599	604	I-Cell
(	605	606	O
RASMCs	606	612	B-Cell
)	612	613	O
infected	614	622	O
with	623	627	O
AdCMV	628	633	O
.	633	634	O
VEGF165	634	641	B-Gene_or_gene_product
(	642	643	O
5	643	644	O
and	645	648	O
20	649	651	O
plaque	652	658	O
-	658	659	O
forming	659	666	O
units	667	672	O
[	673	674	O
pfu	674	677	O
]	677	678	O
per	679	682	O
cell	683	687	B-Cell
)	687	688	O
demonstrated	689	701	O
VEGF	702	706	B-Gene_or_gene_product
mRNA	707	711	O
expression	712	722	O
and	723	726	O
protein	727	734	O
secretion	735	744	O
into	745	749	O
the	750	753	O
supernatant	754	765	O
.	765	766	O

Furthermore	767	778	O
,	778	779	O
the	780	783	O
conditioned	784	795	O
medium	796	802	O
from	803	807	O
these	808	813	O
cells	814	819	B-Cell
enhanced	820	828	O
vascular	829	837	B-Multi-tissue_structure
permeability	838	850	O
in	851	853	O
vivo	854	858	O
.	858	859	O

In	860	862	O
contrast	863	871	O
,	871	872	O
neither	873	880	O
VEGF	881	885	B-Gene_or_gene_product
mRNA	886	890	O
nor	891	894	O
secreted	895	903	O
protein	904	911	O
was	912	915	O
found	916	921	O
in	922	924	O
uninfected	925	935	O
HUVECs	936	942	B-Cell
or	943	945	O
RASMCs	946	952	B-Cell
or	953	955	O
in	956	958	O
cells	959	964	B-Cell
infected	965	973	O
with	974	978	O
the	979	982	O
control	983	990	O
vector	991	997	O
AdCMV	998	1003	O
.	1003	1004	O
beta	1004	1008	B-Gene_or_gene_product
gal	1009	1012	I-Gene_or_gene_product
(	1013	1014	O
where	1014	1019	O
beta	1020	1024	B-Gene_or_gene_product
gal	1025	1028	I-Gene_or_gene_product
is	1029	1031	O
beta	1032	1036	B-Gene_or_gene_product
-	1036	1037	I-Gene_or_gene_product
galactosidase	1037	1050	I-Gene_or_gene_product
)	1050	1051	O
.	1051	1052	O

Assessment	1053	1063	O
of	1064	1066	O
starved	1067	1074	O
HUVECs	1075	1081	B-Cell
at	1082	1084	O
14	1085	1087	O
days	1088	1092	O
demonstrated	1093	1105	O
sixfold	1106	1113	O
more	1114	1118	O
cells	1119	1124	B-Cell
for	1125	1128	O
AdCMV	1129	1134	O
.	1134	1135	O
VEGF165	1135	1142	B-Gene_or_gene_product
-	1142	1143	O
infected	1143	1151	O
HUVECs	1152	1158	B-Cell
(	1159	1160	O
20	1160	1162	O
pfu	1163	1166	O
per	1167	1170	O
cell	1171	1175	B-Cell
)	1175	1176	O
than	1177	1181	O
for	1182	1185	O
either	1186	1192	O
infected	1193	1201	O
or	1202	1204	O
uninfected	1205	1215	O
control	1216	1223	O
cells	1224	1229	B-Cell
.	1229	1230	O

RASMC	1231	1236	B-Cell
proliferation	1237	1250	O
was	1251	1254	O
unaffected	1255	1265	O
by	1266	1268	O
infection	1269	1278	O
with	1279	1283	O
AdCMV	1284	1289	O
.	1289	1290	O
VEGF165	1290	1297	B-Gene_or_gene_product
.	1297	1298	O

When	1299	1303	O
plated	1304	1310	O
in	1311	1313	O
2	1314	1315	O
%	1315	1316	O
serum	1317	1322	O
on	1323	1325	O
dishes	1326	1332	O
precoated	1333	1342	O
with	1343	1347	O
reconstituted	1348	1361	O
basement	1362	1370	B-Cellular_component
membrane	1371	1379	I-Cellular_component
(	1380	1381	O
Matrigel	1381	1389	O
)	1389	1390	O
,	1390	1391	O
HUVECs	1392	1398	B-Cell
infected	1399	1407	O
with	1408	1412	O
AdCMV	1413	1418	O
.	1418	1419	O
VEGF165	1419	1426	B-Gene_or_gene_product
(	1427	1428	O
20	1428	1430	O
pfu	1431	1434	O
per	1435	1438	O
cell	1439	1443	B-Cell
)	1443	1444	O
differentiated	1445	1459	O
into	1460	1464	O
capillary	1465	1474	B-Tissue
-	1474	1475	I-Tissue
like	1475	1479	I-Tissue
structures	1480	1490	I-Tissue
.	1490	1491	O

Under	1492	1497	O
similar	1498	1505	O
conditions	1506	1516	O
,	1516	1517	O
both	1518	1522	O
uninfected	1523	1533	O
HUVECs	1534	1540	B-Cell
and	1541	1544	O
HUVECs	1545	1551	B-Cell
infected	1552	1560	O
with	1561	1565	O
AdCMV	1566	1571	O
.	1571	1572	O
beta	1572	1576	B-Gene_or_gene_product
gal	1577	1580	I-Gene_or_gene_product
did	1581	1584	O
not	1585	1588	O
differentiate	1589	1602	O
.	1602	1603	O

To	1604	1606	O
evaluate	1607	1615	O
the	1616	1619	O
ability	1620	1627	O
of	1628	1630	O
AdCMV	1631	1636	O
.	1636	1637	O
VEGF165	1637	1644	B-Gene_or_gene_product
to	1645	1647	O
function	1648	1656	O
in	1657	1659	O
vivo	1660	1664	O
,	1664	1665	O
either	1666	1672	O
AdCMV	1673	1678	O
.	1678	1679	O

VEGF165	1680	1687	B-Gene_or_gene_product
or	1688	1690	O
AdCMV	1691	1696	O
.	1696	1697	O
beta	1697	1701	B-Gene_or_gene_product
gal	1702	1705	I-Gene_or_gene_product
(	1706	1707	O
2	1707	1708	O
x	1709	1710	O
10	1711	1713	O
(	1713	1714	O
10	1714	1716	O
)	1716	1717	O
pfu	1718	1721	O
)	1721	1722	O
was	1723	1726	O
resuspended	1727	1738	O
in	1739	1741	O
0	1742	1743	O
.	1743	1744	O
5	1744	1745	O
mL	1746	1748	O
Matrigel	1749	1757	O
and	1758	1761	O
injected	1762	1770	O
subcutaneously	1771	1785	O
into	1786	1790	O
mice	1791	1795	B-Organism
.	1795	1796	O

Immunohistochemical	1797	1816	O
staining	1817	1825	O
demonstrated	1826	1838	O
VEGF	1839	1843	B-Gene_or_gene_product
in	1844	1846	O
the	1847	1850	O
tissues	1851	1858	B-Tissue
surrounding	1859	1870	O
the	1871	1874	O
Matrigel	1875	1883	O
plugs	1884	1889	O
containing	1890	1900	O
AdCMV	1901	1906	O
.	1906	1907	O
VEGF165	1907	1914	B-Gene_or_gene_product
up	1915	1917	O
to	1918	1920	O
3	1921	1922	O
weeks	1923	1928	O
after	1929	1934	O
injection	1935	1944	O
,	1944	1945	O
whereas	1946	1953	O
no	1954	1956	O
VEGF	1957	1961	B-Gene_or_gene_product
was	1962	1965	O
found	1966	1971	O
in	1972	1974	O
the	1975	1978	O
control	1979	1986	O
plugs	1987	1992	O
with	1993	1997	O
AdCMV	1998	2003	O
.	2003	2004	O
beta	2004	2008	B-Gene_or_gene_product
gal	2009	2012	I-Gene_or_gene_product
.	2012	2013	O

Two	2014	2017	O
weeks	2018	2023	O
after	2024	2029	O
injection	2030	2039	O
,	2039	2040	O
there	2041	2046	O
was	2047	2050	O
histological	2051	2063	O
evidence	2064	2072	O
of	2073	2075	O
neovascularization	2076	2094	O
in	2095	2097	O
the	2098	2101	O
tissues	2102	2109	B-Tissue
surrounding	2110	2121	O
the	2122	2125	O
Matrigel	2126	2134	O
containing	2135	2145	O
AdCMV	2146	2151	O
.	2151	2152	O
VEGF165	2152	2159	B-Gene_or_gene_product
,	2159	2160	O
whereas	2161	2168	O
no	2169	2171	O
significant	2172	2183	O
angiogenesis	2184	2196	O
was	2197	2200	O
observed	2201	2209	O
in	2210	2212	O
response	2213	2221	O
to	2222	2224	O
AdCMV	2225	2230	O
.	2230	2231	O
beta	2231	2235	B-Gene_or_gene_product
gal	2236	2239	I-Gene_or_gene_product
.	2239	2240	O

Furthermore	2241	2252	O
,	2252	2253	O
the	2254	2257	O
Matrigel	2258	2266	O
plugs	2267	2272	O
with	2273	2277	O
AdCMV	2278	2283	O
.	2283	2284	O
VEGF165	2284	2291	B-Gene_or_gene_product
demonstrated	2292	2304	O
hemoglobin	2305	2315	B-Gene_or_gene_product
content	2316	2323	O
fourfold	2324	2332	O
higher	2333	2339	O
than	2340	2344	O
the	2345	2348	O
plugs	2349	2354	O
with	2355	2359	O
AdCMV	2360	2365	O
.	2365	2366	O
beta	2366	2370	B-Gene_or_gene_product
gal	2371	2374	I-Gene_or_gene_product
.	2374	2375	O

Together	2376	2384	O
,	2384	2385	O
these	2386	2391	O
in	2392	2394	O
vitro	2395	2400	O
and	2401	2404	O
in	2405	2407	O
vivo	2408	2412	O
studies	2413	2420	O
are	2421	2424	O
consistent	2425	2435	O
with	2436	2440	O
the	2441	2444	O
concept	2445	2452	O
that	2453	2457	O
Ad	2458	2460	B-Organism
vectors	2461	2468	O
may	2469	2472	O
provide	2473	2480	O
a	2481	2482	O
useful	2483	2489	O
strategy	2490	2498	O
for	2499	2502	O
efficient	2503	2512	O
local	2513	2518	O
delivery	2519	2527	O
of	2528	2530	O
VEGF165	2531	2538	B-Gene_or_gene_product
in	2539	2541	O
the	2542	2545	O
treatment	2546	2555	O
of	2556	2558	O
ischemic	2559	2567	O
diseases	2568	2576	O
.	2576	2577	O

